{'fraction_non_alphanumeric': 0.027662517289073305, 'fraction_numerical': 0.0, 'mean_word_length': 5.407079646017699, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Is Avastin the right choice of treatment for retinopathy of prematurity?

Off-label use of intravitreal bevacizumab (Avastin ) is an increasingly popular treatment for retinopathy of prematurity (ROP). It has been described as a simpler, cheaper and more effective alternative to conventional laser therapy. But is it really safe to inject a cancer drug into the eyes of a premature infant? The use of bevacizumab is widely debated among neonatologists and ophthalmologists. We asked Christoph Bührer, professor of neonatology, at the Charité University Medical Center in Berlin, and Ann Hellström, professor of paediatric ophthalmology, at Queen Silvia Children’s Hospital, Gothenburg, to share their views about the drug.